|
KMID : 1142020220570000044
|
|
Blood Research
2022 Volume.57 No. 0 p.44 ~ p.48
|
|
|
Challenging issues in the management of cancer-associated venous thromboembolism
|
|
Yhim Ho-Young
|
|
|
Abstract
|
|
|
|
Venous thromboembolism (VTE) is a common complication among patients with cancer and is associated with delays in underlying cancer treatment and increases in morbidity and mortality. Acute and long-term treatments with low-molecular-weight-heparin (LMWH) have been recommended as a standard of care for patients with cancer with VTE for the past 20 years. Direct oral anticoagulants (DOACs) have recently emerged as a new therapeutic modality for cancer-associated VTE because of the convenience of oral administration and rapid onset of action. Our knowledge regarding DOACs for cancer-associated VTD has expanded in recent years. Thus, this study aimed to review recent major pivotal trials comparing DOACs with LMWH for managing cancer-associated VTE. Moreover, a recently updated understanding of DOACs in the treatment of cancer-associated VTE in specific challenging situations is presented.
|
|
|
KEYWORD
|
|
|
Cancer, Direct oral anticoagulant, Venous thromboembolism
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|